Effects of Inhaled Epinephrine on Systemic Allergic Reactions During Allergy Testing, Immunotherapy or Oral Challenges

NCT ID: NCT07038746

Last Updated: 2026-02-05

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 100 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-08-25
• Study Completion Date: 2026-07-31

Brief Summary

The goal of this exploratory study is to evaluate the effects of inhaled epinephrine in subjects, who may not be eligible for the GHL-101 trial, and who are experiencing systemic allergic reaction (SAR) that occur following allergy testing, subcutaneous immunotherapy (SCIT), oral challenges (with food and/or drug) or oral immunotherapy (OIT).

Detailed Description

This is a Phase 1b, multi-center, open label exploratory study evaluating the effects of inhaled epinephrine in patients who are undergoing planned allergy testing, SCIT, oral challenges (with food and/or drug), or OIT and are not eligible for the GHL-101 study. This study will enroll and dose up to 100 patients.

The maximum duration of subject participation is approximately 1 week.

Conditions

Hypersensitivity; Anaphylaxis

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Inhaled Epinephrine

The first inhalation will be administered as soon as possible (i.e., within approximately 30 seconds) following identification of a SAR Grade 2 or higher and confirmation of enrollment by the Principal Investigator. The second inhalation will be administered approximately 10 seconds later, and the subject will be observed for approximately 2 minutes for signs of symptom resolution.

Inhalations will continue in this manner until either:

1. resolution of systemic symptoms (defined as a reduction in SAR Grade to ≤1), or

2. if maximum number of inhalations (8 inhalations) has not been reached, complete resolution of systemic symptoms (defined as reduction in SAR Grade to 0) without exceeding maximum 8 inhalations, or

3. administration of intra-muscular epinephrine, whichever occurs earlier.

If a recurrence of symptoms is observed, administration may continue until a maximum of 8 inhalations is reached.

Group Type: EXPERIMENTAL

Inhaled Epinephrine

Intervention Type: DRUG

0.125 mg per inhalation.

The maximum proposed dose to be administered is 1.0 mg (consisting of 8 inhalations of 0.125 mg over 6 minutes).

Interventions

Inhaled Epinephrine

0.125 mg per inhalation.

The maximum proposed dose to be administered is 1.0 mg (consisting of 8 inhalations of 0.125 mg over 6 minutes).

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Males or females, aged ≥ 12 years with known or suspected allergen sensitivity who can also have a clinical history of immunoglobulin E (IgE)-mediated allergy, including a documented sensitivity to allergens (i.e., positive skin prick test, or positive in vitro serum IgE).

2. Have undergone either a) allergy testing for suspected sensitivity/allergy, b) future oral challenge (food and/or drug) or future OIT to treat existing allergies or c) SCIT AND experienced a SAR Grade 2 or higher, following allergy testing, SCIT, or oral challenges (food and/or drug) for future OIT, and deemed eligible for enrollment by the Principal Investigator.

3. For females of child-bearing potential, not pregnant or lactating, willing to use an acceptable contraception* method between Screening and End-of-Study Visits.

Exclusion Criteria

1. Known reaction or sensitivity to epinephrine or any of the ingredients of inhaled epinephrine.

2. Known history or presence of clinically disease/condition that could confound the results of the study or place the subject at undue or additional risk per the judgment of the Investigator.

3. Abnormal vital signs at screening (i.e., systolic blood pressure: < 90 or >140 mmHg, diastolic blood pressure: < 40 or > 90 mmHg or, heart rate: < 45 or > 100 bpm), respiration rate < 8 or > 20 resp./min.

4. Females who are pregnant, plan to become pregnant or lactating.

5. Participation in another clinical study involving an investigational drug within 30 days prior to screening, an investigational biologic within 60 days prior to screening, or current/planned participation in another interventional study during this study.

6. Previous treatment in this study.

7. Any other reason that, in the opinion of the Investigator, is likely to unfavorably alter subject risk-benefit, confound results, or make it difficult for the subject to fully comply with study requirements.

• Minimum Eligible Age: 12 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Dr. George Luciuk

OTHER

Sponsor Role: lead

Responsible Party

Dr. George Luciuk

President, Chief Medical Officer

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

George H. Luciuk, MD

Role: PRINCIPAL_INVESTIGATOR

Kokua Pharma Inc.

Locations

Kokua Pharma Inc.

Richmond, British Columbia, Canada

Site Status: RECRUITING

Countries

Canada

Central Contacts

George H. Luciuk, MD

Role: CONTACT

gh.luciuk@dr.com

1-604-270-7801

Facility Contacts

George H. Luciuk, MD

Role: primary

gh.luciuk@dr.com

1-604-270-7801

Other Identifiers

GHL-102

Identifier Type: -

Identifier Source: org_study_id